Memory loss is a concern of many people, particularly as they age. Memory loss may be due to depression, stress, medical conditions, or a sign of impending dementia such as Alzheimer’s disease. Lifestyle changes can have a great effect on those with modifiable risk factors. These include hearing loss, hypertension, obesity, smoking, depression, physical inactivity, social isolation, diabetes and sleep disorders. Proper diet can also have a positive effect on retaining memory. We at NervePro teach you of these measures. In addition, identifying the earliest clinical and biological changes to intervene with medication is important. Clinical trials should be considered due to the modest benefit available from current medications.
Dementia is a collective term used to describe a condition when in addition to mild short term memory loss, sufficient difficulties have developed to interfere with daily activities such as driving safely, paying bills, plan and prepare a meal, making appointments and being able to organize the household. We will evaluate those with difficulty to determine which type of dementia one may have. Alzheimer’s disease is the most common cause of dementia. In this condition, deposits of Amyloid and tau protein disrupt neuronal pathways and cause brain cell loss. This buildup can occur for over 15 years prior to dementia being diagnosed and can be detected on an amyloid PET scan.
Present treatments for Alzheimer’s disease include acetylcholinesterase blockers which boost the level of the main memory neurotransmitter (donepezil, Excelon, galantamine), and Namenda which works through the glutamine pathways. At NervePro, we are participating in a clinical trial for mild cognitive impairment and early to Alzheimer’s dementia. Side effects on preliminary studies have been minimal, and existing FDA approved medications can be continued. The medication reduces the amyloid buildup that occurs in Alzheimer’s disease, often 15 years prior to diagnosis and is felt responsible for much of the damage that occurs. Screening procedures include psychometric testing, MRI, amyloid PET and lab tests, all free to participants. After the initial two years, all patients are assured of getting drug and not placebo.
A second study involves those with moderate dementia who have developed fragmented sleep. Those with this common problem often sleep poorly at night, and excessively during the day. A sleep study is included, and lab and medication at no cost to those who qualify.
Make a Research Appointment